(NASDAQ:ENGN) BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, āenGeneā or the āCompanyā), a clinical-stage, non-viral gene therapy company, today announced it has achieved its target enrollment milestone of 100 patients for the pivotal cohort of its ongoing, open-label, multi-cohort Phase 2 LEGEND trial of detalimogene voraplasmid (ādetalimogeneā and previously EG-70) in patients with high-risk, non-muscle invasive bladder cancer (NMIBC). LEGENDās pivotal Cohort 1 is studying detalimo
Related Questions
How will achieving the 100āpatient enrollment milestone in the LEGIT pivotal cohort influence enGeneās shortāterm stock momentum and valuation multiples?
What does the enrollment rate and trial design suggest about the timeline for data readāouts and potential regulatory filing compared to other NMIBC geneātherapy competitors?
What are the potential market size and revenue upside if the PhaseāÆ2 data support a successful launch, and how might that affect longāterm growth forecasts for enGene?